Color Broadens Cancer Expert Medical Opinion Program
Color expanded its Expert Medical Opinion program with a new peer-to-peer service that connects oncologists with cancer specialists.
How AI almost led Dr. Farzad Mostashari down the wrong path on health equity
In a virtual panel discussion about public and population health at J.P. Morgan's annual conference, the CEO of Aledade shared how the quest for efficiency in a world of harried physicians' practices almost led Aledade to use a flawed ML algorithm to engage at-risk patients of those practices.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
From genetic testing to public health, Color now valued at $4.6B
The company started with genetic testing, but expanded to Covid-19 tests and vaccines during the pandemic. It's valuation has tripled since it last raised a funding round valuing it at $1.5 billion in January.
Color hits $1.5B valuation, plans to build on testing infrastructure
The company, which got started in genomic testing, has quickly expanded its services to include providing Covid-19 testing at businesses and universities. With the new funding, it plans to build infrastructure for more preventive health services.
Getting the right data to doctors is next hurdle for precision medicine
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
Helix, Mayo Clinic embark on genomic sequencing study of 100,000 people
The Rochester, Minnesota-based healthcare system and San Mateo, California-based population genomics company plan to launch the study in the next few weeks.
presented by
The Healthcare Payments Industry Faces a Perception Challenge
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Verily, Color partner on delivering genetic information for Project Baseline participants
Color vice president for research and scientific affairs Alicia Zhou explained that there is an ethical obligation to provide information on actionable genes, but costs and logistics have previously made doing so prohibitive.
With new $600M fund, CRV expands into bioengineering investment, adds strategic growth stage deals
In addition to its expansion into bioengineering, the early stage venture capital firm has also shifted its investment strategy to include strategic growth investments.
Color secures widespread coverage for its hereditary cancer test
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is 'yes.'